8 active not recruiting, 5 completed, 1 recruiting. 14 Phase 3.
By phase and status
Follow retatrutide: new trials by email Literature Review of retatrutide trials Research Report on retatrutide
Trials (filtered) newest first · largest first
All 14 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Retatrutide - Obesity, Overweight Phase 3 Active not recruiting 600 2026-01-24 2026-06-09 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight Retatrutide, Placebo - Obesity, Overweight Phase 3 Active not recruiting 250 2025-11-17 2026-04-17 A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Tirzepatide, Retatrutide, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease Phase 3 Recruiting 4500 2025-10-15 2026-10-08 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain Retatrutide, Placebo - Obesity, Overweight Phase 3 Active not recruiting 586 2025-05-29 2026-09-25 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Retatrutide, Placebo - Obesity Phase 3 Active not recruiting 643 2025-03-05 2026-03-03 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Retatrutide, Tirzepatide - Obesity Phase 3 Active not recruiting 800 2024-11-01 2026-07-20 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Retatrutide, Placebo - Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) Phase 3 Active not recruiting 10000 2024-04-30 2026-10-08 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Retatrutide, Placebo - Diabetes Type 2 Phase 3 Completed 537 2024-04-10 2026-03-05 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Retatrutide, Placebo - Type 2 Diabetes Phase 3 Active not recruiting 320 2024-03-15 2026-07-20 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Retatrutide, Semaglutide - Diabetes Mellitus, Type 2 Phase 3 Active not recruiting 1250 2024-02-21 2026-09-28 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Retatrutide, Placebo - Obesity, Overweight Phase 3 Completed 445 2023-08-01 2026-01-21 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight Retatrutide, Placebo - Type 2 Diabetes, Obesity Phase 3 Completed 1152 2023-07-11 2026-07-30 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Retatrutide, Placebo - Obesity, Overweight Phase 3 Completed 2335 2023-07-10 2026-08-21 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease Retatrutide, Placebo - Obesity, Cardiovascular Diseases Phase 3 Completed 1946 2023-05-30 2026-07-30
Conditions studied Obesity (9) · Overweight (6) · Diabetes Mellitus, Type 2 (5) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Cardiovascular Diseases (2) · Kidney Diseases (2) · Renal Insufficiency, Chronic (2) · Sleep Apnea, Obstructive (2) · Atherosclerosis (1) · Cerebrovascular Disorders (1) · Coronary Artery Disease (1) · Death (1) · Diabetes Mellitus (1)
Sponsors Eli Lilly and Company (14)
Countries United States (14) · Argentina (9) · Canada (9) · Mexico (9) · Puerto Rico (8) · United Kingdom (7) · Australia (6) · Poland (6) · Spain (6) · Brazil (5) · India (5) · Hungary (4) · Romania (4) · Germany (3) · Israel (3)
Results publications PMID 41160422 , PMID 42250575 , PMID 42810372 , PMID 42814954
NIH funding 2023 (5) , 2025 (1)